Tiziana life sciences announces anti-cd3 mab research for the treatment of alzheimer's disease to be presented by dr. howard weiner at the international conference on alzheimer's and parkinson's disease and related neurological disorders conference in sweden

New york, march 31, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that dr. howard weiner will present positive data from a study of intranasal anti-cd3 monoclonal antibody in an animal model of alzheimer's disease on april 1, 2023 at the ad/pd 2023 international conference on alzheimer's and parkinson's diseases and related neurological disorders in gothenburg, sweden.
TLSA Ratings Summary
TLSA Quant Ranking